If the roles of urogenital microbiota in PD-L1 expression would be confirmed in the future, urogenital microbiota might be a target for enhancing clinical responses to PD1/PD-L1 inhibitors in the treatment of bladder cancer or other urogenital tract tumors. This evidence concerns the gene PDCD1 and urinary bladder cancer.